Obesity drugs show early promise against the hormonal disorder PMOS, giving a suffering family hope

Charlotte Touzalin, an 18-year-old college student from Colorado, vividly recalls the frustration of struggling with weight gain, irregular periods, and unwanted facial hair that baffled doctors. Her mother, Anne Schultz, had faced similar symptoms for decades, but a recent diagnosis of polyendocrine metabolic ovarian syndrome (PMOS) finally provided answers.

PMOS, affecting 1 in 8 women worldwide, is a hormonal condition that was recently renamed to shift focus away from ovaries and cysts. Unlike Schultz, Touzalin had hope after participating in a study testing GLP-1 drugs, obesity medications that show promise in treating the disorder.

These groundbreaking drugs not only promote weight loss but also improve insulin resistance, hormone balance, and ovulation, all crucial factors in PMOS. Dr. Melanie Cree, who has led studies testing GLP-1 drugs for PMOS, is thrilled by the results, describing them as "incredibly effective" in improving symptoms for women with this condition.

Diagnosing PMOS often takes years due to overlapping symptoms, varying severity, and potential dismissal by doctors. The disorder tends to run in families and is often accompanied by excess weight, although not exclusively so. With no known cause or specific treatment, current management includes symptom control through birth control pills and maintaining weight through diet and exercise.

The primary hormones driving PMOS are insulin and testosterone. Insulin acts like a key to allow blood sugar into cells, while testosterone plays a role in sexual desire, bone density, and muscle mass. Most women with PMOS, regardless of body size, experience insulin resistance, causing the hormone to fail in regulating blood sugar. This excess insulin then reaches the ovaries, stimulating increased testosterone production and leading to issues like skipped periods, severe acne, and facial hair growth.